To establish whether miRNA expression patterns in platelets, monocytes, plasma and endothelial cells differ between subjects with premature CVD and a positive family history of premature CVD as compared to age en sex matched healthy controls.
ID
Source
Brief title
Condition
- Coronary artery disorders
- Arteriosclerosis, stenosis, vascular insufficiency and necrosis
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
MiRNA expression patterns of thrombocytes, monocytes, plasma and endothelial
cells.
Secondary outcome
nvt
Background summary
Cardiovascular disease (CVD) represents the primary cause of human morbidity
and mortality1, underscoring the need for innovative new diagnostic strategies.
Recent studies have identified a powerful role of microRNAs (miRNAs) as highly
useful biomarkers. We expect that subjects with premature cardiovascular
disease have a specific miRNA expression pattern of their blood as compared to
matched healty controls and that therefore miRNA profiling in blood can be used
as novel biomarkers for diagnostic approaches.
Study objective
To establish whether miRNA expression patterns in platelets, monocytes, plasma
and endothelial cells differ between subjects with premature CVD and a positive
family history of premature CVD as compared to age en sex matched healthy
controls.
Study design
Case control study
Intervention
nvt
Study burden and risks
There is no direct benefit or risk for the patients besides the inconvenience
of the venapuncture. New strategies to identify subjects at risk for
cardiovascular disease are needed. If we can determine miRNA as biomarker in a
cohort with premature disease we could possibly use this as a biomarker for CVD
in the future. This could then be used for improved individual risk management.
Besides the inconvenience of the venapuncture controls have a risk of
experiencing side effects of medications. There is a direct benefit for
controls, since a general cardiovascular work-up will lead to a cardiovascular
risk assessment and might lead to treatment if necessary.
Meibergdreef 9
1105 AZ Amsterdam
NL
Meibergdreef 9
1105 AZ Amsterdam
NL
Listed location countries
Age
Inclusion criteria
Cases: men with coronair artery disease under the age of 51 years and a positive family history of premature CVD.
Controls: matched for sex, age and smoking habits
Exclusion criteria
Cases: no cardiovascular event below 51 years
Controles: history or complaints of cardiovascular disease, positive family history of cardiovascular disease, use of medication. Additional exclusion criteria because of carbasaalcalcium and statin administration:
- Allergy for carbasalaatcalcium or simvastatin.
- Liver function disorders defined as the upper normal limit of ALAT and ASAT
- CPK above three time upper normal limit
- Renal impairement
Additional exclusion criteria for carbasalaatcalcium use:
- Gastric pain or complaints with former use
- Gastric bleeding or perforations
- Ulcers in stomach, esophagus or bowels
- Hypoprothrombinemia
Additional exclusion criteria for statin use:
- Consumption of excessive amount of alcohol defined as 21 units/week
- Hypothyoidism
- Familiar muscle disorders
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL29313.018.09 |